Navigation Links
Xeloda in Medical News

Drug Xeloda as effective as Traditional Chemotherapy

According to Drugmaker Roche Holding AG Xeloda oral chemotherapy is proving to be as effective as traditional chemotherapy to treat advanced stomach cancer//. Data from a Phase III study which will be presented at an American Society of Clinical Oncology meeting (ASCO) has shown that Xeloda, al...

Mylan Confirms First-to-File Patent Challenge Relating to Xeloda(R) Cancer Treatment

...nn-La Roche filed a lawsuit April 8 in the U.S. District Court for the District of New Jersey alleging infringement of U.S. Patent No. 5,472,949. xeloda Tablets, 150 mg and 500 mg, had approximately $447 million in sales for the 12 months ending Dec. 31, 2008, according to IMS Health. Currently, Mylan ...

Chinese Colorectal Cancer Drug Market Will More Than Double by 2012

...rongest drivers of the Chinese colorectal drug market during the next five years," stated Jing Wu, M.S., MBA. "We also expect a high uptake of Roche's xeloda -- an oral pro-drug of 5-fluorouracil (5-FU) -- due to its delivery advantage over intravenous 5-FU and its inclusion on the National Reimbursement Dr...

Twenty New Abstracts on Oral Xeloda(R) (capecitabine) Featured at the 31st San Antonio Breast Cancer Symposium

...etastatic breast cancer who were treated with oral xeloda monotherapy compared with vinorelbine monotherapy ...hat metastatic breast cancer patients treated with xeloda monotherapy had statistically significant lower to...ina metastatic breast cancer patients treated with xeloda or taxane monotherapy. -- Dec. 14, 7:00 to...

Pharsight to Present on Oncology Modeling and Simulation at PAGE Annual Meeting

...ology case studies during a dedicated conference session on applications in model-based development: -- June 18: A Modeling Framework to Simulate xeloda Dose Intensity and Survival in Colorectal Cancer. Dr. Claret will present this case study as part of an oral conference session on the strat...

Recurrent low-grade carcinoma of the ovary less responsive to chemo than more common ovarian cancers

...ved in women with platinum-resistant disease to standard chemotherapy agents such as liposomal doxorubicin; topotecan; hexamethylmelamine; oral VP-16; xeloda and gemcitabine. One patient had a partial response to paclitaxel. The overall response rate in this subgroup was 2 percent. Sixty-one (62 percent) ...

Many More Patients Can Now Benefit from Avastin's Proven Survival Benefits

...se (CHMP) positive recommendations for the extended use of both Avastin and xeloda in December 2007. *The final EC decision on Xeloda for its extended use is ...d fluoropyrimidine based chemotherapy and also allows for combinations with xeloda or oxaliplatin. Avastin formerly could only be used in combination with IV ...

Xeloda(R), Taxotere(R) and Herceptin(R) Combination Study Suggests Clinical Benefit in Invasive Breast Cancer with Shortened Treatment Cycle

...he XeNA results demonstrate the potential for oral xeloda to serve as the cornerstone of combination chemoth...fected breast after preoperative administration of xeloda and Taxotere for HER2-negative patients and in com...treatment regimen. HER2-negative patients received xeloda 825 mg/m2 twice a day for 14 days with seven days ...

Tablet is better all round for cancer patients

...s can be unpleasant. The oral chemotherapy drug xeloda (capecitabine) offers fewer side-effects and less ...rch showed that about 71 percent of patients given xeloda were still alive after five years, compared to 68 ...ancer surgery. It found that patients treated with xeloda spent 85 percent less time with their doctor or at...

GlaxoSmithKline’s Tykerb is to Be Started Earlier in Breast Cancer, Study Find

... Phase III study has shown that GlaxoSmithKline's Tykerb along with Roche's xeloda is far better than xeloda alone in women with HER2// positive advanced breast cancer, where the disea...
Xeloda in Medical Technology

New Data Show That Herceptin, Xeloda and Avastin Help Patients With Early and Advanced Breast Cancer Live Longer or Remain Disease Free for Longer

BASEL, Switzerland, Dec. 10 /PRNewswire/ -- New data being presented at the CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) show that Herceptin (trastuzumab), Avastin (bevacizumab) and oral Xeloda (capecitabine) continue to offer new and better treatment options for breast cancer patients al...

New Overall Survival Study Results Confirm Oral Xeloda(R) plus Oxaliplatin (XELOX) is Comparable to FOLFOX-4 for the First-Line Treatment of Advanced Colorectal Cancer

...ue and importance of combination therapy with oral xeloda for the thousands of patients with this insidious ... "We're excited to see the continued promise of xeloda as a cornerstone of combination cancer treatments,...eting also will feature five additional Roche U.S. xeloda abstracts, including a second XELOX abstract. All ...

Data Confirm Avastin(R) Helps Patients With Metastatic Colorectal Cancer Live Even Longer

...well tolerated for CRC patients with yet further chemotherapy combinations, xeloda (capecitabine) and irinotecan (XELIRI) and xeloda and oxaliplatin (XELOX). This data reinforces that Avastin is first choice ...

Nearly 60 New Studies of Oral Xeloda(R) (capecitabine) Featured at the 44th American Society of Clinical Oncology Annual Meeting

...ational, seven-days-on/seven-days-off (7-on/7-off) xeloda regimen versus the current standard xeloda dosing of fourteen-days-on/seven-days-off (14-on/7...proved tumor growth inhibition with the 7-on/7-off xeloda regimen; results support clinical testing of this ...

Novel Xeloda(R) Dosing Schedule May Offer Well-Tolerated Alternative for Treatment of Advanced Breast Cancer

... providing a potential alternative to the standard xeloda dosing of 14 days on and seven days off (14-on/7-o...dule." Efficacy of the 7-on/7-off schedule using xeloda is being determined in a Phase II clinical trial p...as applied to determine that the maximum impact of xeloda treatment in breast cancer patients occurs after s...

Over 30 New Studies of Oral Xeloda(R) Featured at the 2008 Gastrointestinal Cancers Symposium

... - U.S. Data Highlights Oral xeloda versus Standard Infusional Chemotherapy ...ty profile and usage patterns of therapy with oral xeloda to that of intravenous fluorouracil (5-FU) therapy...nical efficacy and tolerability results of a novel xeloda regimen (7/7, or 7 days on, 7 days off) using high...

Positive Xeloda(R) Five-Year Overall Survival Study Data in the Adjuvant Treatment of Colon Cancer Presented at Leading European Cancer Meeting

... Results show five-year overall survival rates for xeloda at 71.4 percent compared to 68.4 percent in the 5-... at the meeting from a previous analysis show that xeloda is also comparable to 5- FU/LV with respect to dis...r overall survival data provide further proof that xeloda can be a safe and effective alternative to the cur...

Avastin Achieves Impressive Rate of Curative Surgery in Patients with Advanced Colorectal Cancer

...ble metastatic disease received Avastin in combination with standard first line chemotherapy; the most common regimens were FOLFOX, XELOX, FOLFIRI and xeloda (capecitabine). The dose of Avastin used was equivalent to 2.5 mg/kg/week (5 mg/kg every 2 weeks with 5-FU-based regimens and 7.5 mg/kg every 3 weeks ...

Xeloda(R) XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium

...the XeNA (Xeloda in NeoAdjuvant) trial, a study of xeloda and docetaxel with or without Herceptin in patient...ndings that validate efficacy and cost benefits of xeloda in breast cancer patients. -- Poster No. A54, [Ge...oche's commitment to exploring the expanded use of xeloda in combination with new therapies. About...

Xeloda XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium

...ta abstracts about its oral chemotherapy treatment xeloda have been accepted for presentation at the 2007 Br...the XeNA (Xeloda in NeoAdjuvant) trial, a study of xeloda and docetaxel with or without Herceptin in patient...ndings that validate efficacy and cost benefits of xeloda in breast cancer patients. -- Poster No. A54, [Ge...
Other Tags
(Date:3/4/2015)... (PRWEB) March 04, 2015 Dr. Christopher ... NuMale Medical Center today lamented the FDA’s recent ... therapy (TRT). He argued that FDA’s conclusions are ... harm men who suffer from testosterone deficiency. , “The ... equivocation” on testosterone replacement therapy,” said Dr. Asandra. “There ...
(Date:3/4/2015)... Austria (PRWEB) March 04, 2015 ... reduce subjectivity in density assessment and help improve ... of numerous abstracts accepted for presentation at the ... 2015. Ten abstracts - eight posters and ... Volpara Solutions’ automated breast density and quantitative breast ...
(Date:3/4/2015)... 2015 Starting February 2015, Dr. Joseph ... procedures at their new location in Surrey. , In ... and Dr. Gabriel Chu also provide comprehensive ophthalmology services, ... named Fraser Valley Cataract and Laser (FVCL). This state ... College of Physicians and Surgeons of British Columbia. Fraser ...
(Date:3/4/2015)... Georgia (PRWEB) March 04, 2015 State ... part of the School of Public Health at Georgia ... The funds were awarded by Georgia’s Division of Family ... to support the DFCS Call Center. , The ... maltreatment by providing information and referral services that promote ...
(Date:3/4/2015)... La Farge, Wis. (PRWEB) March 04, 2015 ... a leading organic brand, today announced its cause campaign to ... has gone viral and is making a difference to Bros ... million views on Youtube and Facebook. The video was ... and was featured in Forbes, Mashable and Digiday, among other ...
Breaking Medicine News(10 mins):Health News:NuMale’s Dr. Christopher Asandra: FDA Suffering from “Premature Equivocation” on Issue of Testosterone and Risks 2Health News:Research Finds Use of Volpara Solutions’ Quantitative Breast Imaging Tools Help Reduce Subjectivity in Density Assessment and Improve Breast Cancer Risk Prediction 2Health News:Research Finds Use of Volpara Solutions’ Quantitative Breast Imaging Tools Help Reduce Subjectivity in Density Assessment and Improve Breast Cancer Risk Prediction 3Health News:Research Finds Use of Volpara Solutions’ Quantitative Breast Imaging Tools Help Reduce Subjectivity in Density Assessment and Improve Breast Cancer Risk Prediction 4Health News:Research Finds Use of Volpara Solutions’ Quantitative Breast Imaging Tools Help Reduce Subjectivity in Density Assessment and Improve Breast Cancer Risk Prediction 5Health News:King LASIK relocates to Surrey, British Columbia 2Health News:State Funds Child Abuse Helpline Housed At Georgia State 2Health News:ORGANIC VALLEY URGES PUBLIC TO SAVE THE BROs: CAMPAIGN EARNS MORE THAN 1M VIEWS ON YOUTUBE 2Health News:ORGANIC VALLEY URGES PUBLIC TO SAVE THE BROs: CAMPAIGN EARNS MORE THAN 1M VIEWS ON YOUTUBE 3
(Date:2/13/2015)... ACT Genomics Co., Ltd., a cancer ... cancer genomic information into precision diagnosis and personalized ... US$ 8 million in the its first private funding ... Taiwan , ACT Genomics has developed comprehensive ... to implement next generation sequencing (NGS) and multiplex ...
(Date:2/9/2015)...  Lintec of America recently announced an exclusive license ... macrostructures, including sheets, yarns and ribbons, developed at the ... the vast industrial resources of the global Lintec Group, ... of America is forming the Nano-Science and Technology Center ... on scaling up the manufacturing and commercialization of nano ...
(Date:2/5/2015)... IRVINE, Calif. , Jan. 27, 2015 ... trusted provider of globally deployed, innovative test ... today announced the delivery of its ... Martin Space Systems Company (LMSSC). GENASYS is ... the demands of mission-critical applications that require ...
Breaking Biology News(10 mins):ACT Genomics Raises $8 Million in its First Private Funding Round 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 4
Other Contents